BMRN earnings call for the period ending December 31, 2019.
News & Analysis: BioMarin Pharmaceutical
The gene therapy maker's novel medicine has the potential to take over a highly competitive market and offer growth opportunities for investors.
The agency expects to make a decision by Aug. 21, 2020.
The company is developing a novel enzyme-based treatment for phenylketonuria (PKU), but it faces growing competition from potentially curative gene therapies.
These stocks could thump the broader markets this year.
If approved, Valrox could become the most expensive drug in the world.
Fast-approaching catalysts could make these biotech stocks top performers this year.
The business reported a handful of positive developments.
BioMarin and Sarepta Therapeutics should be top growth plays in the next decade.
BioMarin's stock is poised for big gains in 2020. Here's why.